Activation of the epidermal growth factor receptor in optic nerve astrocytes leads to early and transient induction of cyclooxygenase-2

Investigative Ophthalmology and Visual Science

Volumn 46, Issue 6, 2005, Pages 2035-2041

  Zhang, Xu ^a   Neufeld, Arthur H ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PROSTAGLANDIN E2; PROTEIN TYROSINE KINASE INHIBITOR; ENZYME INHIBITOR; EPIDERMAL GROWTH FACTOR; N-(2-CYCLOHEXYLOXY-4-NITROPHENYL)METHANESULFONAMIDE; NITROBENZENE DERIVATIVE; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEIN TYROSINE PHOSPHATASE; SULFONAMIDE; TYRPHOSTIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CELL NUCLEUS MEMBRANE; CONTROLLED STUDY; CULTURE MEDIUM; ENZYME INDUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPLANT; GLAUCOMA; IMMEDIATE EARLY GENE; IMMUNOBLOTTING; IMMUNOCYTOCHEMISTRY; INFLAMMATION; MEDIATOR RELEASE; NERVE INJURY; NERVE TRANSECTION; NONHUMAN; OPTIC NERVE; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; RAT; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; TISSUE INJURY; ANIMAL; BIOSYNTHESIS; CELL CULTURE; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; FLUORESCENT ANTIBODY TECHNIQUE; METABOLISM; OPTIC NERVE INJURY; WISTAR RAT;

ANIMALS; ASTROCYTES; CELLS, CULTURED; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPIDERMAL GROWTH FACTOR; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; NITROBENZENES; OPTIC NERVE; OPTIC NERVE INJURIES; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROTEIN-TYROSINE-PHOSPHATASE; RATS; RATS, WISTAR; RECEPTOR, EPIDERMAL GROWTH FACTOR; SULFONAMIDES; TYRPHOSTINS;

EID: 22144488836     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.04-1473     Document Type: Article

References (44)

1. Hernandez MR, The optic nerve head in glaucoma: role of astrocytes in tissue remodeling. Prog Retin Eye Res. 2000;19:297-321.
2. Hatten ME, Liem RK, Shelanski ML, Mason CA. Astrogliá in CNS injury. Glia. 1991;4:233-243.
3. Zhang X, Cheng M, Chintala SK. Optic nerve ligation leads to astrocyte-associated matrix metalloproteinase-9 induction in the mouse retina. Neurosci Lett. 2004;356:140-144.
4. Eddleston M, Mucke L. Molecular profile of reactive astrocytes: implications for their role in neurologic disease. Neuroscience. 1993;54:15-36.
5. Dong Y, Benveniste EN. Immune function of astrocytes. Glia. 2001;36:180-190.
6. Hinz B, Brune K. Cyclooxygenase-2: 10 years later. J Pharmacol Exp Ther. 2002;300:367-375.
7. Dubois RN, Abramson SB, Crofford L, et al. Cyclooxygenase in biology and disease. FASEB J. 1998;12:1063-1073.
8. Huh YH, Kim SH, Kim SJ, Chun JS. Differentiation status-dependent regulation of cyclooxygenase-2 expression and prostaglandin E2 production by epidermal growth factor via mitogen-activated protein kinase in articular chondrocytes. J Biol Chem. 2003;278:9691-9697.
9. Portanova JP, Zhang Y, Anderson GD, et al. Selective neutralization of prostaglandin E2 blocks inflammation, hyperalgesia, and interleukin 6 production in vivo. J Exp Med. 1996;184:883-891.
10. Yamagata K, Andreasson KI, Kaufmann WE, Barnes CA, Worley PF. Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids. Neuron. 1993;11:371-386.
11. Iadecola C, Niwa K, Nogawa S, et al. Reduced susceptibility to ischemic brain injury and N-methyl-D-aspartate-mediated neurotoxicity in cyclooxygenase-2-deficient mice. Proc Natl Acad Sci USA. 2001;98:1294-1299.
12. Sennlaub F, Valamanesh F, Vazquez-Tello A, et al. Cyclooxygenase-2 in human and experimental ischemic proliferative retinopathy. Circulation. 2003;108:198-204.
13. Ju WK, Kim KY, Neufeld AH. Increased activity of cyclooxygenase-2 signals early neurodegenerative events in the rat retina following transient ischemia. Exp Eye Res. 2003;77:137-145.
14. Richardson CM, Sharma RA, Cox G, O'Byrne KJ. Epidermal growth factor receptors and cyclooxygenase-2 in the pathogenesis of non-small cell lung cancer: potential targets for chemoprevention and systemic therapy. Lung Cancer. 2003;39:1-13.
15. Mestre JR, Chan G, Zhang F, et al. Inhibition of cyclooxygenase-2 expression: an approach to preventing head and neck cancer. Ann NY Acad Sci. 1999;889:62-71.
16. Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science. 2004;305:1163-1167.
17. Xu XC. COX-2 inhibitors in cancer treatment and prevention, a recent development. Anticancer Drugs. 2002;13:127-137.
18. Mestre JR, Subbaramaiah K, Sacks PG, et al. Retinoids suppress epidermal growth factor-induced transcription of cyclooxygenase-2 in human oral squamous carcinoma cells. Cancer Res. 1997;57:2890-2895.
19. Matsuura H, Sakaue M, Subbaramaiah K, et al. Regulation of cyclooxygenase-2 by Interferon gamma and transforming growth factor alpha in normal human epidermal keratinocytes and squamous carcinoma cells: role of mitogen-activated protein kinases. J Biol Chem. 1999;274:29138-29148.
20. Ashida M, Bito T, Budiyanto A, Ichihashi M, Ueda M. Involvement of EGF receptor activation in the induction of cyclooxygenase-2 in HaCaT keratinocytes after UVB. Exp Dermatol. 2003;12:445-452.
21. Nieto-Sampedro M, Gomez-Pinilla F, Knauer DJ, Broderick JT. Epidermal growth factor receptor immunoreactivity in rat brain astrocytes: response to injury. Neurosci Lett. 1988;91:276-282.
22. Planas AM, Justicia C, Soriano MA, Ferrer I. Epidermal growth factor receptor in proliferating reactive glia following transient focal ischemia in the rat brain. Glia. 1998;23:120-129.
23. Ferrer I, Alcantara S, Ballabriga J, et al. Transforming growth factor-alpha (TGF-alpha) and epidermal growth factor-receptor (EGF-R) immunoreactivity in normal and pathologic brain. Prog Neurobiol. 1996;49:99-123.
24. Ding H, Shannon P, Lau N, et al. Oligodendrogliomas result from the expression of an activated mutant epidermal growth factor receptor in a RAS transgenic mouse astrocytoma model. Cancer Res. 2003;63:1106-1113.
25. Oyesiku NM, Evans CO, Houston S, et al. Regional changes in the expression of neurotrophic factors and their receptors following acute traumatic brain injury in the adult rat brain. Brain Res. 1999;833:161-172.
26. Arun D, Gutmann DH. Recent advances in neurofibromatosis type 1. Curr Opin Neurol. 2004;17:101-105.
27. Liu B, Neufeld AH. Activation of epidermal growth factor receptor signals induction of nitric oxide synthase-2 in human optic nerve head astrocytes in glaucomatous optic neuropathy. Neurobiol Dis. 2003;13:109-123.
28. Neufeld AH, Liu B. Glaucomatous optic neuropathy: when glia misbehave. Neuroscientist. 2003;9:485-495.
29. Hernandez MR, Igoe F, Neufeld AH. Cell culture of the human lamina cribrosa. Invest Ophthalmol Vis Sci. 1988;29:78-89.
30. Cheng HF, Wang JL, Zhang MZ, Wang SW, McKanna JA, Harris RC. Genetic deletion of COX-2 prevents increased renin expression in response to ACE inhibition. Am J Physiol. 2001;280:F449-F456.
31. Neufeld AH, Hernandez MR, Gonzalez M, Geller A. Cyclooxygenase-1 and cyclooxygenase-2 in the human optic nerve head. Exp Eye Res. 1997;65:739-745.
32. Liu B, Neufeld AH. Activation of epidermal growth factor receptor causes astrocytes to form cribriform structures: Glia. 2004;46:153-168.
33. Ellis AG, Nice EC, Weinstock J, Levitzki A, Burgess AW, Webster LK. High-performance liquid Chromatographic analysis of the tyrphostin AG1478, a specific inhibitor of the epidermal growth factor receptor tyrosine kinase, in mouse plasma. J Chromatogr B Biomed Sci Appl. 2001;754:193-199.
34. Futaki N, Takahashi S, Yokoyama M, Arai I, Higuchi S, Otomo S. NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. Prostaglandins. 1994;47:55-59.
35. Eng LF, Ghirnikar RS. GFAP and astrogliosis. Brain Pathol. 1994;4:229-237.
36. Ridet JL, Malhotra SK, Privat A, Gage FH. Reactive astrocytes: cellular and molecular cues to biological function. Trends Neurosci. 1997;20:570-577.
37. Levison SW, Jiang FJ, Stoltzfus OK, Ducceschi MH. IL-6-type cytokines enhance epidermal growth factor-stimulated astrocyte proliferation. Glia. 2000;32:328-337.
38. Rabchevsky AG, Weinitz JM, Coulpier M, Fages C, Tinel M, Junier MP. A role for transforming growth factor alpha as an inducer of astrogliosis. J Neurosci. 1998;18:10541-10552.
39. Faber-Elman A, Solomon A, Abraham JA, Marikovsky M, Schwartz M. Involvement of wound-associated factors in rat brain astrocyte migratory response to axonal injury: in vitro simulation. J Clin Invest. 1996;97:162-171.
40. Suzuki K, Ikegaya Y, Matsuura S, Kanai Y, Endou H, Matsuki N. Transient upregulation of the glial glutamate transporter GLAST in response to fibroblast growth factor, insulin-like growth factor and epidermal growth factor in cultured astrocytes. J Cell Sci. 2001;114:3717-3725.
41. Barna BP, Mattera R, Jacobs BS, et al. Epidermal growth factor regulates astrocyte expression of the interleukin-4 receptor via a MAPK-independent pathway. Cell Immunol. 2001;208:18-24.
42. Coffey RJ, Hawkey CJ, Damstrup L, et al. Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells. Proc Natl Acad Sci USA. 1997;94:657-662.
43. Parfenova H, Parfenov VN, Shlopov BV, et al. Dynamics of nuclear localization sites for COX-2 in vascular endothelial cells. Am J Physiol. 2001;281:C166-C178.
44. Neufeld AH. Pharmacologic neuroprotection with an inhibitor of nitric oxide synthase for the treatment of glaucoma. Brain Res Bull. 2004;62:455-459.